Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline Pharmaceuticals Limited (IN:GLAXO)
:GLAXO
Total Valuation
GlaxoSmithKline Pharmaceuticals Limited has a market cap or net worth of ₹556.62B. The enterprise value is ₹336.04B.
Market Cap₹556.62B
Enterprise Value₹336.04B
Share Statistics
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding169,406,040
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
GlaxoSmithKline Pharmaceuticals Limited’s return on equity (ROE) is 0.48 and return on invested capital (ROIC) is 59.24%.
Return on Equity (ROE)0.48
Return on Assets (ROA)0.23
Return on Invested Capital (ROIC)59.24%
Return on Capital Employed (ROCE)0.81
Revenue Per Employee11.68M
Profits Per Employee2.89M
Employee Count3,211
Asset Turnover0.91
Inventory Turnover2.89
Valuation Ratios
The current PE Ratio of GlaxoSmithKline Pharmaceuticals Limited is 51.08. GlaxoSmithKline Pharmaceuticals Limited’s PEG ratio is 0.61.
PE Ratio51.08
PS Ratio0.00
PB Ratio12.89
Price to Fair Value24.28
Price to FCF50.98
Price to Operating Cash Flow46.35
PEG Ratio0.61
Income Statement
In the last 12 months, GlaxoSmithKline Pharmaceuticals Limited had revenue of 37.49B and earned 9.28B in profits. Earnings per share was 54.76.
Revenue37.49B
Gross Profit23.58B
Operating Income17.79B
Pretax Income12.60B
Net Income9.28B
EBITDA11.77B
Earnings Per Share (EPS)54.76
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
GlaxoSmithKline Pharmaceuticals Limited pays an annual dividend of ₹54, resulting in a dividend yield of 1.28%
Dividend Per Share₹54
Dividend Yield1.28%
Payout Ratio48.36%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.74
52-Week Price Change32.26%
50-Day Moving Average3.10K
200-Day Moving Average2.62K
Relative Strength Index (RSI)52.60
Average Volume (3m)8.39K
Important Dates
GlaxoSmithKline Pharmaceuticals Limited upcoming earnings date is Aug 1, 2025, TBA (Confirmed).
Last Earnings DateMay 13, 2025
Next Earnings DateAug 1, 2025
Ex-Dividend DateMay 30, 2025
Financial Position
GlaxoSmithKline Pharmaceuticals Limited as a current ratio of 1.79, with Debt / Equity ratio of 0.89%
Current Ratio1.79
Quick Ratio1.54
Debt to Market Cap0.00
Net Debt to EBITDA-1.18
Interest Coverage Ratio1.36K
Taxes
In the past 12 months, GlaxoSmithKline Pharmaceuticals Limited has paid 3.32B in taxes.
Income Tax3.32B
Effective Tax Rate0.26
Enterprise Valuation
GlaxoSmithKline Pharmaceuticals Limited EV to EBITDA ratio is 39.06, with an EV/FCF ratio of 36.30.
EV to Sales12.27
EV to EBITDA39.06
EV to Free Cash Flow36.30
EV to Operating Cash Flow35.65
Balance Sheet
GlaxoSmithKline Pharmaceuticals Limited has ₹25.22B in cash and marketable securities with ₹99.50M in debt, giving a net cash position of -₹25.12B billion.
Cash & Marketable Securities₹25.22B
Total Debt₹99.50M
Net Cash-₹25.12B
Net Cash Per Share-₹148.27
Tangible Book Value Per Share₹114.41
Margins
Gross margin is 60.49%, with operating margin of 47.44%, and net profit margin of 24.74%.
Gross Margin60.49%
Operating Margin47.44%
Pretax Margin33.60%
Net Profit Margin24.74%
EBITDA Margin31.40%
EBIT Margin29.62%
Analyst Forecast
The average price target for GlaxoSmithKline Pharmaceuticals Limited is ₹2,250.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹2,250.00
Price Target Upside-19.36% Downside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―